175 results on '"Ozieranski, Piotr"'
Search Results
2. Payments to healthcare organisations reported by the medical device industry in Europe from 2017 to 2019: An observational study
3. Professional and governmental policy on community pharmacy: A 10-year policy review and comparative analysis (2008–2017)
4. Advancing international comparison of pharmaceutical industry funding of patient advocacy: Focus on Denmark
5. Drug company methodologies used for reporting in the UK pharmaceutical industry payment transparency database between 2015-2019: A content analysis
6. Delays in dealing with complaints against drug companies are growing, BMJ finds
7. Is there evidence for the racialization of pharmaceutical regulation? Systematic comparison of new drugs approved over five years in the USA and the EU
8. Pharmaceutical industry self-regulation and non-transparency: country and company level analysis of payments to healthcare professionals in seven European countries
9. The Emerging Social Science Literature on Health Technology Assessment: A Narrative Review
10. Pharmaceutical industry payments to NHS trusts in England: A four-year analysis of the Disclosure UK database
11. Authors’ reply to Fell
12. Professional stakeholders’ expectations for the future of community pharmacy practice in England: a qualitative study
13. Unethical pharmaceutical marketing: a common problem requiring collective responsibility
14. How not to waste a crisis : a qualitative study of problem definition and its consequences in three hospitals
15. The whistleblowing drama behind Astellas’s suspension from the ABPI
16. Shedding light on the HTA consultancy market: Insights from Poland
17. Evaluating the transparency of pharmaceutical company disclosure of payments to patient organisations in the UK
18. Patterns of alternative access: Unpacking the Slovak extraordinary drug reimbursement regime 2012-2016
19. Alternative access schemes for pharmaceuticals in Europe: Towards an emerging typology
20. Pharmacy users' perceptions, awareness and future expectations of community pharmacy in England: a focus group study.
21. Governing drug reimbursement policy in Poland: The role of the state, civil society, and the private sector
22. Payments to healthcare organisations reported by the medical device industry in Europe from 2017 to 2019: an observational study
23. Comparing pharmaceutical company payments in the four UK countries: a cross-sectional and social network analysis
24. Evaluation of Financial and Nonfinancial Conflicts of Interest and Quality of Evidence Underlying Psoriatic Arthritis Clinical Practice Guidelines: Analysis of Personal Payments From Pharmaceutical Companies and Authors’Self‐CitationRate in Japan and the United States
25. Evaluation of Financial and Nonfinancial Conflicts of Interest and Quality of Evidence Underlying Psoriatic Arthritis Clinical Practice Guidelines: Analysis of Personal Payments From Pharmaceutical Companies and Authors' Self‐Citation Rate in Japan and the United States
26. Walkrounds in Practice: Corrupting or Enhancing a Quality Improvement Intervention? A Qualitative Study
27. Evaluation of Financial and Nonfinancial Conflicts of Interest and Quality of Evidence Underlying Psoriatic Arthritis Clinical Practice Guidelines: Analysis of Personal Payments From Pharmaceutical Companies and Authors’ Self‐CitationRate in Japan and the United States
28. Pricing strategies, executive committee power and negotiation leverage in New Zealand's containment of public spending on pharmaceuticals
29. Tip of the Iceberg? Country- and Company-Level Analysis of Drug Company Payments for Research and Development in Europe
30. Disclosure of Pharmaceutical Industry Funding of Patient Organisations in Nordic Countries: Can Industry Self-Regulation Deliver on its Transparency Promise?
31. sj-docx-2-joh-10.1177_00207314221083871 - Supplemental material for Disclosure of Pharmaceutical Industry Funding of Patient Organisations in Nordic Countries: Can Industry Self-Regulation Deliver on its Transparency Promise?
32. sj-docx-5-joh-10.1177_00207314221083871 - Supplemental material for Disclosure of Pharmaceutical Industry Funding of Patient Organisations in Nordic Countries: Can Industry Self-Regulation Deliver on its Transparency Promise?
33. sj-docx-4-joh-10.1177_00207314221083871 - Supplemental material for Disclosure of Pharmaceutical Industry Funding of Patient Organisations in Nordic Countries: Can Industry Self-Regulation Deliver on its Transparency Promise?
34. sj-docx-1-joh-10.1177_00207314221083871 - Supplemental material for Disclosure of Pharmaceutical Industry Funding of Patient Organisations in Nordic Countries: Can Industry Self-Regulation Deliver on its Transparency Promise?
35. The politics of health technology assessment in Poland
36. How Do Institutional Conflicts of Interest Between Pharmaceutical Companies and the Healthcare Sector Become Corrupt? A Case Study of Scholarship Donations Between Department of Clinical Anesthesiology, Mie University, and Ono Pharmaceutical in Japan
37. Capitalizing on transparency: Commercial surveillance and pharmaceutical marketing after the Physician Sunshine Act
38. Drug company payments to General Practices in England: Cross-sectional and social network analysis
39. A ‘patient–industry complex’? Investigating the financial dependency of UK patient organisations on drug company funding
40. Accessibility and quality of drug company disclosures of payments to healthcare professionals and organisations in 37 countries: a European policy review
41. Divergent spender: State‐societal and meso‐organisational mechanisms in the containment of public spending on pharmaceuticals in a liberal capitalist democracy
42. A hidden web of policy influence: The pharmaceutical industry’s engagement with UK’s All-Party Parliamentary Groups
43. Culture and behaviour in the English National Health Service: overview of lessons from a large multimethod study
44. Failure of Responsive Regulation? Pharmaceutical Marketing, Corporate Impression Management and Off-Label Promotion of Enzalutamide in Europe
45. Under-reported relationship: a comparative study of pharmaceutical industry and patient organisation payment disclosures in the UK (2012–2016)
46. A 'patient–industry complex'? Investigating the financial dependency of UK patient organisations on drug company funding.
47. Five years of pharmaceutical industry funding of patient organisations in Sweden: Cross-sectional study of companies, patient organisations and drugs
48. Analysis of Pharmaceutical Industry Payments to UK Health Care Organizations in 2015
49. Exposing drug industry funding of UK patient organisations
50. Disclosure of payments by pharmaceutical companies to healthcare professionals in the UK: analysis of the Association of the British Pharmaceutical Industry’s Disclosure UK database, 2015 and 2016 cohorts
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.